EDSS SCORE SHEET PDF

The Expanded Disability Status Scale (EDSS) and the Functional Systems Score (FSS) together describe severity of disability in patients with MS. With the help of the FSS, the examiner rates your disability on the EDSS scale. It ranges from 0 to 10, with half points for greater specificity. EDSS. • Expanded Disability Status Scale. – Devised by John Kurtzke in the s and modified A modification of the original Kurtzke scale.

Author: Melmaran Maladal
Country: Malta
Language: English (Spanish)
Genre: Education
Published (Last): 11 September 2007
Pages: 444
PDF File Size: 7.92 Mb
ePub File Size: 5.55 Mb
ISBN: 420-2-68970-939-7
Downloads: 9221
Price: Free* [*Free Regsitration Required]
Uploader: Aranos

The introduction of new criteria edsz the clinical and imaging diagnosis have changed the course for MS treatment and disease progression because some drugs must be used early in cases of clinically isolated syndromes 37, Restricted to wheelchair and may need aid in transferring. More recently, a new score was developed based on the initial EDSS score and the time of disease progression for each patient.

Most of the studies used the EDSS as an index of disability to detect reduction, stabilization or progression.

In situations when there is subjectivity and FS deficits do not correspond to a specific EDSS level, a range is provided. Severe ataxia, all limbs. Able to walk without aid or rest for m 6.

VISUAL (OPTIC) FUNCTIONAL SYSTEM SCORE

IMM and IMS drugs reduce the number of relapses, but there is still controversy as to whether these drugs exert a significant influence on the long-term disabilities suffered by some MS patients Significant disability but self-sufficient and up and about some 12 hours a day. N Engl J Med ; A double blind study on azathioprine efficacy in multiple sclerosis: Dementia or chronic brain syndrome — severe or incompetent.

  HERBERT SILBERER PDF

With the MSSS the time of disease already is calculated and we expected a reduction or stabilization of disability score with the treatment. Another study that used BET over a period of 16 years also showed a progression in disability, but demonstrated that individuals achieved the same degree of disability when using the medication for a period of esss.

The lack of statistical difference between initial and final treatment score in the EDSS for some groups AVO, Sheef, COP and MITcould suggest disease stabilization or a reduction of disabilities, but these groups had less patients than the others with statistical significant data.

In need of almost constant catheterization. We evaluated the progression of disability using the EDSS score 24 because this index can be recorded based on the clinical manifestation and neurological examination recorded in the past decades. The final EDSS score showed variation for the reduction of disability up to four points and increased until five points, and a similar variation occurred with several IMM drugs 7. Axonal transec tion in the lesions of multiple sclerosis.

  JKS 1AD PDF

All the patients received the same amount of medication despite the age, gender, weight and disease duration Table 1. Unable to perform coordinated movements due to ataxia. Disability severe enough to eds full daily activities. To save favorites, you must log in. The progressive disability in multiple sclerosis MS remains a therapeutic problem despite numerous medications available. Retains many self-care functions. The efficacy of azathioprine in relapsing-remitting multiple sclerosis.

EDSS Calculator online (multiple sclerosis)

Up and about in wheelchair some 12 hours a day. The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Crit Rev Immunol ; Severe nystagmus, marked extraocular weakness, or moderate disability of other cranial nerves. To answer these questions will require studies correlating antibodies against interferon, the major histocompatibility complex and additional pharmacogenetic studies.

J Neurol Neurosurg Psychiatry ; However, MIT has been reserved for cases that do not respond to immunomodulator IMM drugs because of its toxicity 5,6.

No statistically significance difference was found in the MSSS between initial and final scores in the whole group or treatment sub-groups. Unable to walk beyond approximately 5m even with aid.

This article was written by admin